| Year |
Citation |
Score |
| 2015 |
Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM, Arbustini E, Erdem G, Jin XY, et al. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. American Heart Journal. 169: 605-12. PMID 25965707 DOI: 10.1016/J.Ahj.2015.01.011 |
0.321 |
|
| 2014 |
Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. American Heart Journal. 168: 37-44.e5. PMID 24952858 DOI: 10.1016/J.Ahj.2014.02.012 |
0.329 |
|
| 2013 |
Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Annals of Internal Medicine. 159: 797-805. PMID 24490264 DOI: 10.7326/0003-4819-159-12-201312170-00004 |
0.313 |
|
| 2004 |
Stylianou M, Follmann DA. The accelerated biased coin up-and-down design in phase I trials. Journal of Biopharmaceutical Statistics. 14: 249-60. PMID 15027512 DOI: 10.1081/Bip-120028518 |
0.358 |
|
| 2003 |
Stylianou M, Proschan M, Flournoy N. Estimating the probability of toxicity at the target dose following an up-and-down design. Statistics in Medicine. 22: 535-43. PMID 12590412 DOI: 10.1002/Sim.1351 |
0.553 |
|
| 2002 |
Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics. 58: 171-7. PMID 11890313 DOI: 10.1111/J.0006-341X.2002.00171.X |
0.551 |
|
| Show low-probability matches. |